Conference and Workshop on New Frontiers in diagnosis, screening and management of inherited cancer syndromes

遗传性癌症综合征诊断、筛查和管理新领域会议和研讨会

基本信息

批准号：
9133834
负责人：
OLUFUNMILAYO F. OLOPADE
金额：
$ 1万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9133834
关键词：
Address Advisory Committees Advocate Area Award Cancer Patient Case Based Learning Chicago Cities Clinical Collaborations Communication Communities Complex Data Development Diagnosis Educational workshop Evaluation Faculty Family Family member Gastroenterologist Generations Genes Genetic Genetic Counseling Genetic screening method Genome Genomics Goals Gynecologist Health Personnel Healthcare Inherited International Knowledge Leadership Location Malignant Neoplasms Manuscripts Mentors Minority Nature Nurses Oncologist Participant Patient risk Patients Physician Assistants Physicians Prevention Prevention approach Primary Care Physician Professional Education Publishing Research Research Personnel Risk Risk Assessment Schedule Series Surgeon Syndrome System Technology Testing Travel Universities Update Woman base cancer care cancer genetics cancer prevention cancer risk career clinical care clinical practice evidence base exome exome sequencing frontier genetic counselor genetic pedigree genetic variant genome sequencing high risk improved individualized prevention innovation interest learning community lectures member multidisciplinary next generation sequencing novel novel strategies personalized health care posters public health relevance response screening symposium targeted cancer therapy

项目摘要

DESCRIPTION (provided by applicant): Rapid advances in genetic and genomic technologies have revolutionized our approach to cancer risk assessment, screening, prevention and targeted cancer therapies, heralding the era of precision healthcare. The introduction of affordable next generation sequencing (NGS) testing including multi-gene panels and whole exome or genome sequencing provides a wealth of data on both rare and common genetic variants. While these technologies enable personalized cancer risk assessment and cancer prevention, they also require novel approaches to genetic counseling, interpretation of results and responsible communication of this complex information. While professional education in the technology and application of genomics to clinical care is urgently needed especially for community practitioners and trainees, it is not readily available and there are no opportunities for hands-on case based learning. To address the changing landscape and provide evidence-based professional education, we propose a unique interdisciplinary yearly conference series to highlight clinical innovations in cancer risk assessment and prevention. The format will include state-of the art lectures, panel discussions, small breakout sessions for case based learning and poster presentations. Our overall goal is to improve the quality of cancer risk assessment and precision prevention approaches by providing an interdisciplinary educational forum in which to disseminate new knowledge in translational genomics and evidence-based clinical care of high-risk patients and their at risk family members. In addition to our leadership team, a conference advisory committee (CAC) composed of external members with exceptional expertise in cancer genetics, who will advise on the conference agendas and speakers. Each year, we will feature different invited faculty who are experts in their field to provide state-of- the-art lectures and participate in panel and case discussions. At each subsequent conference, we will address our specific aims by disseminating updates at the cutting edge of research and clinical developments in the field. To develop a learning community, we will curate Pedigrees with accompanying clinical information submitted by workshop participants and publish an annual conference Proceedings. Our target audience includes interdisciplinary health care providers for cancer patients (oncologists, gastroenterologists, gynecologists, primary care physicians and surgeons), nurses, physician assistants and genetic counselors from community and academic practices. By offering merit- and need-based travel awards, we will provide special opportunities for trainees, junior investigators, women and minorities to participate fully in the workshops and publish with senior mentors. The locations will alternate between downtown Chicago (2016, 2018 and 2020) and City of Hope in Duarte, CA (2017 and 2019). By tracking a number of metrics and due to the dynamic nature of the emerging field of Precision Healthcare, we will alter our conference agenda to accommodate new developments and remain up-to-date and relevant to clinical practice.

描述（由申请人提供）：遗传和基因组技术的快速进步彻底改变了我们的癌症风险评估、筛查、预防和癌症治疗方法，预示着精准医疗保健时代的到来，包括有针对性地引入负担得起的下一代测序（NGS）测试。多基因组和全外显子组或基因组测序提供了有关罕见和常见遗传变异的大量数据，虽然这些技术能够实现个性化癌症风险评估和癌症预防，但它们还需要新的遗传咨询、结果解释和负责任的沟通方法。这些复杂的信息。迫切需要基因组学技术及其在临床护理中的应用方面的教育，特别是对于社区从业者和学员来说，这种教育并不容易获得，也没有机会进行基于案例的实践学习，以应对不断变化的情况并提供基于证据的专业知识。在教育方面，我们提出了一个独特的跨学科年度会议系列，以突出癌症风险评估和预防方面的临床创新，会议形式将包括最先进的讲座、小组讨论、基于案例的学习和海报展示的小型分组会议。提高癌症风险评估的质量通过提供跨学科教育论坛来传播精准预防方法，传播高危患者及其高危家庭成员的转化基因组学和循证临床护理方面的新知识。除了我们的领导团队外，还有一个会议咨询委员会 (CAC)。由在癌症遗传学领域具有杰出专业知识的外部成员组成，他们将为会议议程和演讲者提供建议。每年，我们都会邀请不同领域的专家来提供最先进的讲座并参加小组讨论。以及案例讨论。在会议上，我们将通过传播该领域最前沿的研究和临床进展来实现我们的具体目标，为了建立一个学习社区，我们将整理参与者研讨会提交的谱系以及随附的临床信息，并出版我们的年度会议记录。目标受众包括癌症患者的跨学科医疗保健提供者（肿瘤科医生、胃肠病学家、妇科医生、初级保健医生和外科医生）、护士、医生助理以及来自社区和学术实践的遗传咨询师。将为学员、初级研究员、女性和少数族裔提供充分参与研讨会并与高级导师一起发表论文的特殊机会。地点将在芝加哥市中心（2016 年、2018 年和 2020 年）和加利福尼亚州杜阿尔特的希望之城（2017 年和 2017 年）之间轮流举行。 2019）。通过跟踪一些指标，并且由于精准医疗这一新兴领域的动态性质，我们将改变我们的会议议程，以适应新的发展并保持最新状态并与临床相关。实践。